RNA动力学会影响白血病细胞系对转录干扰的反应
Izabela Todorovski1,2, Mary-Jane Tsang1,2, Breon Feran3,4
1Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.
NAR cancer
|October 7, 2024
概括
mRNA衰变速率,而不仅仅是产量,决定了癌症药物选择性. 快速衰变的基因对转录抑制剂更敏感. 调节mRNA周转为白血病提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 针对失调的转录是癌症治疗的关键策略,特别是在白血病中.
- 小分子抑制剂向基体含蛋白 (BRD),P300/cAMP-响应元素结合蛋白 (CBP) 和循环依赖基因酶 (CDK) 破坏致癌基因表达.
- 这些抑制剂的选择性可能受到后转录过程的影响.
研究的目的:
- 量化评估转录后调节对转录抑制的反应中的作用.
- 研究mRNA生产和衰变动力学如何影响癌症治疗中的药物选择性.
- 通过调节白血病的mRNA循环,探索新的治疗策略.
主要方法:
- 采用多omics分析来测量mRNA生产和衰变动力学.
- 在转录抑制下对mRNA周转率的定量评估.
- 涉及3'未翻译区域 (UTR) 交换c-MYC转录的实验.
- 调查针对ELAVL1调节转录后途径的研究.
主要成果:
- mRNA衰变速率,而不是单独的产生速率,显著影响转录抑制剂的选择性.
- 由转录抑制剂下调的基因通常表现出快速的mRNA生产和周转.
- 通过3' UTR修饰稳定c-MYC转录使其对转录向不敏感,而不会废除治疗效果.
- 调节后转录途径,如ELAVL1,可以使长寿mRNA对转录抑制敏感.
结论:
- mRNA动力学是癌症中对转录扰乱的治疗反应的关键决定因素.
- 转录后调节,特别是mRNA衰变,在向转录的抗癌药物的选择性中起着重要作用.
- 向转录后途径为白血病提供了可行的组合治疗方法,提高了转录抑制剂的疗效.
相关概念视频
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
DNA Damage can Stall the Cell Cycle
9.1K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.1K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


